로딩 중…
지수 로딩 중…
이엔셀
456070· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩4,630-0.96%
2026-11-02
Financials
Valuation Metrics
이엔셀's Market Cap is ₩511B. At end of 2025 it was ₩2005B. Ranked #1689 of 2,410 in KR market (top 70%), #1017 of 1,631 on KOSDAQ (top 62%), #183 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 79%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 51.07B KRW | KR#1,689/2,410 Sec#183/231 |
| Revenue | 4.16B KRW | KR#2,341/2,410 Sec#201/231 |
| Net Income | -19.62B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 55.08B KRW | KR#2,157/2,410 Sec#190/231 |
| Net Assets | 27.86B KRW | KR#2,195/2,410 Sec#200/231 |
| Employees | 112 | KR#1,553/2,410 Sec#121/231 |
| Value | ||
| P/B | 1.83x | KR#1,945/2,410 Sec#143/231 |
| P/S | 12.26x | KR#2,299/2,410 Sec#173/231 |
| FCF Yield | -26.12% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -70.43% | KR#2,312/2,410 Sec#210/231 |
| ROA | -35.62% | KR#2,325/2,410 Sec#206/231 |
| Op. Margin | -437.31% | KR#2,350/2,410 Sec#203/231 |
| Revenue Growth | -27.06% | KR#2,191/2,410 Sec#196/231 |
| Financial Health | ||
| Debt Ratio | 97.73% | KR#1,533/2,410 Sec#175/231 |
| Total Debt | 9.77B KRW | KR#1,630/2,410 Sec#147/231 |
| FCF | -13.34B KRW | KR#1,786/2,410 Sec#161/231 |
| Cash | 21.40B KRW | KR#1,211/2,410 Sec#85/231 |
| Current Ratio | 7.06x | KR#172/2,410 Sec#38/231 |
| Performance | ||
| 1Y Return | -60.26% | KR#2,157/2,410 Sec#200/231 |
| 1M Return | -22.83% | KR#1,934/2,410 Sec#192/231 |
| From 52W High | -77.90% | KR#2,248/2,410 Sec#202/231 |
| 1Y MDD | -77.22% | KR#2,219/2,410 Sec#194/231 |
| Trading | ||
| Volume | 56,200 shares | KR#1,261/2,410 Sec#126/231 |
| Trading Value | 260.0M KRW | KR#1,313/2,410 Sec#140/231 |
| Foreign Own. | 3.96% | KR#1,056/2,410 Sec#94/231 |
| Per Share | ||
| EPS | -1,779 KRW | KR—/2,410 Sec—/231 |
| BPS | 2,526 KRW | KR#1,961/2,410 Sec#156/231 |
Company Info
Based in Seoul, South Korea, Encell Co. Ltd., established in February 2018, focuses on the research, development, and manufacturing of biopharmaceuticals. The company offers tailored pharmaceutical development services, guiding projects from their initial concept through to regulatory approval.